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Summary
Prostate cancer clusters in some families, and an esti-
mated 5%–10% of all cases are estimated to result from
inheritance of prostate cancer–susceptibility genes. We
previously reported evidence of linkage to the 1q24-25
region (HPC1) in 91 North American and Swedish fam-
ilies each with multiple cases of prostate cancer (Smith
et al. 1996). In the present report we analyze 40 (12
original and 28 newly identified) Swedish families with
hereditary prostate cancer (HPC) that, on the basis of
40 markers spanning a 25-cM interval within 1q24-25,
have evidence of linkage. In the complete set of families,
a maximum two-point LOD score of 1.10 was observed
at D1S413 (at a recombination fraction [v] of .1), with
a maximum NPL (nonparametric linkage) Z score of
1.64 at D1S202 ( ). The evidence of linkage toP  .05
this region originated almost exclusively from the subset
of 12 early-onset (age !65 years) families, which yielded
a maximum LOD score of 2.38 at D1S413 ( ) andv  0
an NPL Z score of 1.95 at D1S422 ( ). EstimatesP  .03
from heterogeneity tests suggest that, within Sweden, as
many as 50% of early-onset families had evidence of
linkage to the HPC1 region. These results are consistent
with the hypothesis of linkage to HPC1 in a subset of
families with prostate cancer, particularly those with an
early age at diagnosis.
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Introduction
Several epidemiological studies have demonstrated that
prostate cancer aggregates in some families. Estimates
of the relative risk for first-degree relatives of men with
prostate cancer has been in the range 1.5–8.7 (Steinberg
et al. 1990; Spitz et al. 1991; Gro¨nberg et al. 1996). In
general, the relative risk increases with an increase in
the number of affected individuals in the families and
with a decrease in the age at diagnosis of prostate cancer
in relatives (Steinberg et al. 1990). Segregation analyses
in families with prostate cancer suggest that hereditary
prostate cancer (HPC) is inherited in an autosomal dom-
inant mode (Carter et al. 1992a; Gro¨nberg et al. 1997a).
Other epidemiological studies have suggested that a re-
cessive or X-linked inheritance also is present in a subset
of families with HPC (Monroe et al. 1995; Narod et al.
1995), since the relative risk for an individual with an
affected brother are higher than that for an individual
with an affected father. This observation has very re-
cently been confirmed through linkage analysis ( Xu et
al. 1998)
In 1996 the first prostate cancer–susceptibility locus
(HPC1) was mapped, to chromosome 1q24-25 (Smith
et al. 1996). The initial linkage was reported in 91 fam-
ilies with HPC (i.e., families with at least three members
effected with prostate cancer) that were from North
America or Sweden. The maximal multipoint LOD score
was 5.43 under heterogeneity. In a follow-up study
(Gro¨nberg 1997b), the majority of the evidence for link-
age was derived from families with a greater number
(i.e., at least four) of affected individuals who had early-
onset (mean age !65 years) prostate cancer. So far, five
independent data sets have been reported that have at-
tempted to confirm linkage to chromosome 1q24-25.
Two of the studies have been able to confirm linkage to
HPC1; the first study was an analysis of 20 families with
HPC and reported a maximum NPL (nonparametric
linkage) Z score of 1.72 ( ) at marker D1S466P  .0451
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Table 1
Characteristics of 40 Swedish Families with HPC
FAMILIES IN WHICH
MEAN AGE AT ONSET IS
OVERALL!65 years 165 years
No. of families 12 28 40
Mean age at onset (years) 61.0 71.1 68.0
No. affected/family (range) 3.83 (3–6) 4.78 (3–10) 4.5 (3–10)
No. affected and typed/family (range) 3.5 (2–6) 3.75 (3–9) 3.68 (2–9)
(Cooney et al. 1997). The second study was of 56 fam-
ilies and reported an NPL Z score of 1.91 ( )P  .036
(Hsieh et al. 1997). Three other data sets have not been
able to confirm the linkage to HPC1 (McIndoe et al.
1997; Berthon et al. 1998; Eeles et al 1998).
There are several potential problems in the mapping
of genes causing HPC. Prostate cancer is diagnosed at
a late age (in Sweden, mean age at diagnosis is 74
years)—and HPC is reported as having been diagnosed
only 7–8 years earlier. Prostate cancer is also a common
disease in elderly men, with a lifetime risk, in the Swedish
population, of 15% at age 85 years. These facts make
the problem of phenocopies potentially large, since it is
difficult to distinguish, solely on the basis of age, be-
tween sporadic and hereditary cases. Genetic heteroge-
neity is an obvious problem, since linkage to HPC1 has
been reported in only ∼30% of families with HPC (Smith
et al. 1996).
In the present study, we have studied 40 families with
HPC that have been collected throughout Sweden, in an
attempt to confirm linkage to HPC1 on 1q24-25, with
special attention to age at diagnosis in the families.
Families and Methods
Families
Families with HPC have been examined by our insti-
tution since 1995 and have been identified mainly on
the basis of referrals from urologists throughout Sweden.
We have received ∼300 referrals during the past 3 years.
From these referrals we have selected for our study 40
families with HPC, from which we have collected at least
three DNA samples (blood or tissue) from each of the
men with prostate cancer (table 1). Twelve of these fam-
ilies were included in our earlier report (Smith et al.
1996). However, in two families the affected status has
been changed since the first report (two men have sub-
sequently been diagnosed as having prostate cancer),
and, in all families, more markers have been typed to
establish haplotypes. Blood has been collected for DNA
extraction, both from affected men and their spouses
and from the children, so that inferred genotypes can be
determined. From the files of different pathology de-
partments in Sweden, we have extensively collected par-
affin-embedded tissue samples from men with prostate
cancer. A single experienced pathologist reviewed all tis-
sue samples, and microdissection was performed to en-
rich tumor tissue versus normal tissue. Only normal tis-
sue was used for genotyping. All diagnoses of prostate
cancer in the families were confirmed both by reference
to the Swedish National Cancer Registry and direct ex-
amination of medical records.
Genotyping
Details of DNA extraction and genotyping have been
described in an earlier report (Smith et al. 1996). Ge-
notyping was performed by means of an ABI Prism 377
DNA sequencer, and data analysis was performed with
ABI Prism GeneScan Analysis 2.1 and ABI Prism Gen-
otyper 2.0, to allocate the alleles. The genotyping was
performed both at Umea˚ University and at the National
Human Genome Research Institute, with the same mark-
ers and PCR protocol.
Genotyping of 28 families (families 2–40) was per-
formed with 40 multiplex markers that were from the
D1S2799–D1S1660 interval and that spanned the 25-
cM region of interest. A list of markers is available from
the authors on request. In 12 families (families 41–55),
only five markers were genotyped: D12S452, D1S218,
D1S158, D1S422, and D1S413.
Statistical Analysis
Both parametric and NPL approaches were used in
this study. Both a parametric two-point analysis and
multipoint analysis were used, as described in detail in
previous reports (Smith et al. 1996; Gro¨nberg et al.
1997b), and a dominant disease allele with a frequency
of .003 was assumed. Affected men were assumed to be
carriers of a rare dominant gene, with a fixed 15% phe-
nocopy rate. All unaffected men !75 years of age and
all women were assumed to be of unknown phenotype.
In men 175 years of age, the lifetime penetrance of gene
carriers was estimated to be 63%, and the lifetime risk
of prostate cancer for noncarriers was 16% in this age
class. The computer software packages FASTLINK and
ANALYZE were used for two-point analysis. In both
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Table 2
Results of Parametric Two-Point Linkage and of Multipoint Analysis and Nonparametric Multipoint Linkage, for Eight Markers
in 1q24-25 in 40 Swedish HPC Families, by Mean Age at Diagnosis of Prostate Cancer
GROUP AND MARKER (POSITION [cM])
TWO-POINT
LOD SCORE AT v 
PARAMETRIC
MULTIPOINT
LOD SCORE
NONPARAMETRIC
ANALYSIS
.0 .1 .3 NPL Z P
All families:
D1S452 (.0) 13.12 1.47 .21 .00 .21 .57
D1S218 ( 2.3) 13.19 2.78 .16 .00 .44 .66
D1S2883 (7.5) 5.86 .11 .55 .12 .84 .20
D1S212 (7.6) 8.94 .55 .46 .02 .53 .29
D1S158 (14.9) 21.70 3.21 .14 .11 .95 .17
D1S202 (17.6) 5.89 .23 .20 .31 1.64 .05
D1S422 (21.1) 11.26 .64 .54 .23 1.39 .09
D1S413 (26.5) 2.88 1.10 .63 .28 .75 .22
Families in which age at onset is !65 years ( ):n  12
D1S452 (.0) 3.73 .49 .05 .00 .01 .48
D1S218 ( 2.3) 2.18 .43 .07 .09 .29 .37
D1S2883 (7.5) .21 .58 .2 .88 1.49 .08
D1S212 (7.6) 1.17 .96 .31 .88 1.48 .08
D1S158 (14.9) 2.89 .11 .24 1.05 1.73 .05
D1S202 (17.6) .05 .19 .06 1.04 1.71 .05
D1S422 (21.1) .54 1.03 .39 1.05 1.95 .03
D1S413 (26.5) 2.38 1.70 .48 1.09 1.79 .04
Families in which age at onset is 165 years ( ):n  28
D1S452 (.0) 9.44 1.5 .05 .00 .24 .58
D1S218 ( 2.3) 10.51 1.83 .06 .00 .71 .76
D1S2883 (7.5) 6.07 .69 .35 .00 .04 .46
D1S212 (7.6) 10.11 1.51 .15 .00 .32 .61
D1S158 (14.9) 18.71 3.1 .36 .00 .01 .47
D1S202 (17.6) 5.84 .42 .14 .00 .84 .19
D1S422 (21.1) 10.82 1.67 .15 .00 .40 .33
D1S413 (26.5) 5.08 .62 .15 .00 .26 .59
the multipoint parametric analysis and the NPL analysis
and when creating haplotypes, we used all the infor-
mation from the 40 typed markers (in families 2–40),
together with the software package GENEHUNTER.
The admixture test as implemented in HOMOG (Ott
1985) was used to test for genetic heterogeneity and to
estimate the proportion of linked families (a). Blood
samples from 50 unaffected Swedish men were used as
controls, for calculation of the allele frequencies in the
Swedish population, for the 40 markers in the analysis.
Results
The results of the parametric and the nonparametric
analysis of 8 selected markers ranging from D1S452 to
D1S413 are summarized in Table 2. For all 40 families,
a maximum multipoint NPL Z score of 1.64 ( )P  .05
at D1S202 and a maximum two-point LOD score (at a
recombination fraction [v] of .1) of 1.10 at D1S413 were
observed. The maximum NPL Z score for the 28 families
not reported previously was 1.45 ( ) at markerP  .07
D1S2877 (∼5.0 cM telomeric of D1S158).
When the data were stratified on the basis of mean
age at diagnosis of prostate cancer in the families (i.e.,
!65 years [ ] vs. 165 years [ ]), the evidencen  12 n  28
of linkage to the 1q24-25 region was seen mostly in
families with an early age at onset. In the 12 families
with an early age at onset, the NPL Z score was signif-
icant for several markers in the region, with a maximum
multipoint NPL Z score of 1.95 ( ) at D1S422,P  .03
and the multipoint parametric analysis yielded a peak
LOD score of 1.09 ( ) close to marker D1S413.P  .05
Most of the LOD scores in the parametric analysis were
positive for the markers in this region in this subset of
families, with a maximum two-point LOD score of 2.38
at D1S413 ( ). When the three families (families 2,v  0
17, and 27) previously reported (Smith et al. 1996) were
excluded from the analysis, the maximum NPL Z score
for the remaining nine families was 1.17 at D1S422
( ). By contrast, there was virtually no evidenceP  .12
for linkage in families in which the average age at onset
was 165 years. The scores are negative in these 28 fam-
ilies—a maximum two-point LOD score of only 0.35 at
D1S2883 and an NPL Z score of 0.85 ( ) atP  .19
D1S202 were observed. Figure 1 shows the multipoint
NPL Z scores for all 40 typed markers, for both the
early-onset families and the late-onset families. When
the proportion of families with linkage was estimated
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Figure 1 Multipoint NPL Z scores for 40 markers in the 1q 24-25 region in 40 Swedish families with HPC, divided by mean age at
onset of diagnosis of prostate cancer in the family.
under the assumption of heterogeneity, a was 50% in
the early-onset families and was 0% in the late-onset
families.
In 8/12 (67%) of the early-onset families, all affected
individuals within a single family share the same hap-
lotype in the entire 1q24-25 region; however, we ob-
served no founder haplotype in these families. By con-
trast, only 3/28 (11%) of the affected men in the
late-onset families share the same haplotype within the
HPC1 region. In figure 2, the largest family with HPC
in our study (family 032) is shown with haplotypes for
seven markers spanning the HPC1 region. This family
has prostate cancer in two generations and three differ-
ent cousinships. The mean age at onset in this family is
71 years. Eight of the 10 men affected with prostate
cancer in this family share the same haplotype in region
1q24-25. However, there are two men with prostate can-
cer in two different cousinships not sharing this hap-
lotype, thereby making both the overall multipoint LOD
score and the NPL Z score negative for this family. Since
the lifetime risk of prostate cancer in Sweden is 13% at
age 85 years, it is possible that 1 or 2 of the 10 affected
men have sporadic prostate cancer and that the family
has linkage to the HPC1 region.
Discussion
In the 40 Swedish families with HPC, the multipoint
NPL Z score is 1.64 ( ). Of these 40 families, 12P  .05
were included in the first report of linkage to the HPC1
locus (Smith et al. 1996), and the maximum NPLZ score
of the remaining 28 families is 1.45 ( ). In a fol-P  .07
low-up study of the 79 North American families in-
cluded in the first study (Gro¨nberg et al. 1997b), the
evidence of linkage to the HPC1 locus was mainly con-
fined to early-onset families. The NPL Z score was 5.57
( ) for early-onset families and was onlyP  .000009
0.70 ( ) in late-onset families. In the present re-P  .23
port, there are 12 early-onset families (9 of which had
not been reported previously) in which the NPL Z score
is significant. The maximum NPL Z score for these fam-
ilies is 1.95 ( ) at D1S422 (table 2 and fig. 1),P  .033
with an estimated 50% of the families linked when het-
erogeneity is assumed. We have genotyped only 12 fam-
ilies with early-onset HPC, so the LOD scores and NPL
Z scores are not to be expected to be higher, since the
average score per family is almost equivalent to that in
the North American families in the first linkage report
(Smith et al. 1996). In most families, 40 markers span-
ning a 25-cM region have been typed, to ensure that
maximum information is obtained from each family and
to provide a stable linkage result. A fact that further
supports evidence for linkage in these early-onset fam-
ilies is that, in 8/12 (67%) of them, all affected men
share the same haplotype in this region. It is not sur-
prising that linkage to HPC1 is strongest in early-onset
families, since similar findings have been presented in
the initial reports of linkage to the breast can-
cer–susceptibility genes BRCA1 and BRCA2. In the
Breast Cancer Linkage Consortium’s report of 214 fam-
Figure 2 Family 032, with HPC and haplotypes following markers D1S452, D1S2883, D1S212, D1S158, D1S202, D1S422, and D1S413 in the 1q24-25 region
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ilies with hereditary breast cancer, the strongest evidence
of linkage to BRCA1 was in families with breast/ovarian
and in families with early-onset (at age !45 years) breast
cancer (Easton et al. 1993). Almost no evidence of link-
age was seen in families in which the average age at
onset was 145 years, an age that is 20 years younger
than the average age at onset of sporadic breast cancer.
When the BRCA1 and BRCA2 genes were later iden-
tified, mutations were identified mostly in families with
a very early age at onset—for example, 44.5 years in 34
Swedish families with BRCA1 mutations (Johannsson et
al. 1996). The same results have been seen in hereditary
nonpolyposis colon cancer, in which the majority of fam-
ilies with MLH1 and MSH2 mutations are in early-onset
(mean age !50 years) families that meet the Amsterdam
criteria (Wijnen et al. 1997).
There are conflicting data with regard to linkage to
the HPC1 locus. Two reports have been able to confirm
the linkage (Cooney et al. 1997; Hsieh et al. 1997), but
three others have been unable to do so (McIndoe et al.
1997; Berthon et al. 1998; Eeles et al. 1998). There are
several possible explanations for these discrepant results.
Since the evidence for linkage, in both the Swedish fam-
ilies that we have studied and the families studied at
Johns Hopkins University, is provided mainly by families
with early-onset (age !65 years) prostate cancer, it is
crucial to investigate HPC families meeting these criteria,
to be able to confirm any linkage. It is difficult to esti-
mate, on the basis of the published reports, what pro-
portion of families fulfill these criteria. The number of
genotyped affected persons in each family is also of im-
portance, since strong evidence of linkage is difficult to
obtain if only two or three affected individuals are gen-
otyped in each family. In the families that we studied,
we genotyped, on average, 3.83 affected men, since we
could obtain and use archival tissue samples from de-
ceased men with prostate cancer. Age at diagnosis of
prostate cancer is highly dependent on the diagnostic
traditions among physicians in a particular area. The
introduction of PSA (prostate-specific antigen) screening
in the general population—and, in particular, in high-
risk families—will lower the age at diagnosis by 5
years, on average (Carter et al. 1992b) On the other
hand, in areas in which men do not seek medical atten-
tion until they experience pain due to bone metastasizes
or other symptoms, the diagnosis is probably 10 years
later, compared with cases detected by PSA screening in
asymptomatic men (Carter et al. 1992b). This is illus-
trated by family 032 (fig. 2), which originated from a
rural area in northern Sweden and in which several men
with prostate cancer were diagnosed at late stages, thus
substantially affecting the mean age at diagnosis of pros-
tate cancer. A great majority of the families in the present
and in the initial linkage report (Smith et al 1996) were
identified before the introduction of PSA screening. This
might not be the case in some studies in which no linkage
to the 1q 24-25 region was found (McIndoe et al 1997;
Berthon et al. 1998).
It is also likely that the introduction of PSA screening
increases the number of phenocopies in the families with
HPC, since the recommendation today is that annual
screening in these high-risk families should begin at age
40 years. In later-onset families, the likelihood of phe-
nocopies is even higher, which makes it even more dif-
ficult to find linkage in those families. Locus heteroge-
neity in families with HPC is obvious, since, even in
highly selected families, the HPC1 locus cannot be re-
sponsible for the disease in 150% of the families with
HPC. A recent report (Berthon et al. 1998) has suggested
this; it shows that both a multipoint LOD score, under
the assumption of heterogeneity, of 2.2 and a two-point
LOD of 2.7 at 1q42-43, suggesting an additional locus
more distal on the 1q arm.
In conclusion, we have found significant evidence of
linkage to the HPC1 locus on 1q24-25 in Swedish fam-
ilies with HPC that have an early age at onset (i.e., !65
years). However, the mapping of prostate can-
cer–susceptibility genes is going to be difficult, owing to
the following factors: locus heterogeneity, a high phe-
nocopy rate, the fact that no specific phenotypic features
of HPC have yet been identified, and the difficulty of
finding large informative families with many affected
individuals. These factors might explain the conflicting
results of linkage to the HPC1 locus that have been
published by different groups thus far.
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